Text and Data Mining valid from 2017-03-27
Received: 20 April 2016
Accepted: 20 February 2017
First Online: 27 March 2017
: The authors have the following conflicts to declare: Within the last three years, Prof. Hegerl was an advisory board member for Lilly, Lundbeck, Takeda Pharmaceuticals, Servier and Otsuka Pharma; and a speaker for Bristol-Myers Squibb, Medice Arzneimittel, Novartis and Roche Pharma. Prof. Himmerich received speaker honoraria from AstraZeneca, Lilly and Servier, consulting fees from Bristol-Myers Squibb and chemical substances for study support from Astra Zeneca, Novartis and Wyeth. Dr. Mergl had a Consultancy Agreement with Nycomed, a Takeda company.